Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coombs test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    27 result(s) found for: Coombs test. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-017434-45 Sponsor Protocol Number: 64,185-202 Start Date*: Information not available in EudraCT
    Sponsor Name:InfaCare Pharmaceutical Corporation
    Full Title: A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates with Hyperbilirubinemia
    Medical condition: Neonatal hyperbilirubinemia Hiperbilirubinemia neonatal
    Disease: Version SOC Term Classification Code Term Level
    14.0 10019805 - Hepatobiliary disorders 10020580 Hyperbilirubinaemia neonatal PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005304-14 Sponsor Protocol Number: AL0205PR Start Date*: 2007-01-09
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Design of optimally-diagnostic skin test solutions for diagnosis of sensitisation to a 6-grass pollen mixture, house dust mite (Dermatophagoides pteronyssinus), birch pollen and mugwort pollen and ...
    Medical condition: Sensitisation to one or more allergens of 6-grass pollen mixture (Holcus lanatus, Dactylis glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca elatior), house dust mite (Dermatophago...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036664 Prick test LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001194-29 Sponsor Protocol Number: OSHO #075 Start Date*: 2008-01-11
    Sponsor Name:Universität Leipzig
    Full Title: An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy
    Medical condition: Patients with acute myeloid leukemia not eligible for or resistant to chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004055-37 Sponsor Protocol Number: ALXN1830-WAI-201 Start Date*: 2020-05-06
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia
    Medical condition: WAIHA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002611-27 Sponsor Protocol Number: GAM10-03 Start Date*: 2008-10-27
    Sponsor Name:Octapharma AG
    Full Title: Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID)
    Medical condition: Primary Immundeficiency Diseases (PID)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064859 Primary immunodeficiency syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004105-28 Sponsor Protocol Number: 291-420 Start Date*: 2006-06-20
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.
    Medical condition: Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC).
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045265 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) NL (Ongoing) GR (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005406-24 Sponsor Protocol Number: IIL-FOLL05 Start Date*: 2006-01-30
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Phase III multicentric IIL study, three randomized arms (R-CVP vs R-CHOP vs R-FM),for treatment of patients with stage II-IV follicular lymphoma
    Medical condition: Stage II-IV Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016897 Follicle centre lymphoma diffuse small cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003482-17 Sponsor Protocol Number: 291-418 Start Date*: 2006-03-03
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
    Medical condition: Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045265 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Prematurely Ended) ES (Ongoing) GR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019673-15 Sponsor Protocol Number: BMT-AZA Start Date*: 2010-07-15
    Sponsor Name:Universit� Cattolica del Sacro Cuore
    Full Title: A open label, phase 2, non randomized, multicentre trial to assess the feasibility of induction treatment with 5-azacitidine (5-AZA) followed by allogeneic stem cell transplantation (allo-SCT) or ...
    Medical condition: myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028533 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005679-18 Sponsor Protocol Number: GMX04 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
    Medical condition: Primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2007-001015-28 Sponsor Protocol Number: LLC 2007 SA Start Date*: 2007-07-27
    Sponsor Name:CHU TOURS
    Full Title: Single-agent rituximab as maintenance treatment versus observation after combined induction immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years...
    Medical condition: The trial compares single-agent rituximab as maintenance treatment versus observation after combined immunochematherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001507-35 Sponsor Protocol Number: AZA PH GL 2003 CL 001 Start Date*: 2005-03-07
    Sponsor Name:Pharmion Corporation
    Full Title: A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatm...
    Medical condition: The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative dis...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10028533 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-001211-90 Sponsor Protocol Number: ALXN1830-WAI-202 Start Date*: 2021-08-11
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA)
    Medical condition: Warm Autoimmune Hemolytic Anemia (WAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-011017-24 Sponsor Protocol Number: ADNC-0726 Start Date*: 2009-08-03
    Sponsor Name:LFB Biotechnologies
    Full Title: A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a ...
    Medical condition: Prophyllaxis against RhD isoimmunisation during pregnancy (anti-D prophylaxis) Treatment of RhD negative individuals after incompatible transfusions with blood components containing RhD-positive r...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019513 Hemolytic disease of fetus or newborn, due to isoimmunization LLT
    9.1 10044360 Transfusion with incompatible blood LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001015-82 Sponsor Protocol Number: ALXN1840-WD-302 Start Date*: 2021-11-26
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric particip...
    Medical condition: Wilson Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004811-31 Sponsor Protocol Number: GIMEMA MDS 0205 Start Date*: 2006-05-16
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO
    Full Title: An open label, phase II, non randomized, clinical trial of chemotherapy treatment with 5-Azacytidine plus valproic acid and eventually atra for patients diagnosed with Intermediate II and high risk...
    Medical condition: Intermediate II and high risk Myelodysplastic syndrome MDS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003812-22 Sponsor Protocol Number: P903-23 Start Date*: 2011-10-31
    Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories)
    Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA LT (Completed) LV (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002203-18 Sponsor Protocol Number: P903-31 Start Date*: 2012-07-18
    Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories)
    Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With...
    Medical condition: Community-acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035664 Pneumonia PT
    14.1 10021881 - Infections and infestations 10004051 Bacterial pneumonia, unspecified LLT
    14.1 10021881 - Infections and infestations 10060946 Pneumonia bacterial PT
    14.1 10021881 - Infections and infestations 10010120 Community acquired pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-012072-28 Sponsor Protocol Number: MO22468 Start Date*: 2009-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio randomizado en fase IIIb de MabThera® (rituximab) agregado a quimioterápia, bendamustina o clorambucilo, en pacientes con leucemia linfática crónica. A randomized Phase IIIb study of MabTh...
    Medical condition: Pacientes con leucemia linfática crónica (LLC) en primera linea o segunda línea (máximo de una línea de tratamiento previa) con necesidad de tratamiento. (En España, solo se incluirán pacientes en ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) FR (Completed) FI (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004371-19 Sponsor Protocol Number: ARC1779-004 Start Date*: 2007-11-20
    Sponsor Name:Archemix Corp.
    Full Title: A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders
    Medical condition: von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP) in remission, acute TTP, and von Willebrand Disease Type- 2b (vWD-2b).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037563 Purpura thrombopenic thrombotic LLT
    9.1 10047715 Von Willebrand's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 20:27:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA